Microarray technology displays the complexities of the humoral immune response

Expert Review of Molecular Diagnostics

Volumn 11, Issue 1, 2011, Pages 5-8

  Stafford, Phillip ^a   Johnston, Stephen ^a  

^a ARIZONA STATE UNIVERSITY   (United States)

Author keywords

antibody; B cell repertoire; biomarker; humoral immune response; immunosignature; mRNA display; peptide array; phage display

Indexed keywords

ANTIBODY; INFLUENZA VACCINE; MESSENGER RNA;

CANCER PREVENTION; CHRONIC DISEASE; DNA MICROARRAY; HUMAN; HUMORAL IMMUNITY; MICROARRAY ANALYSIS; REVIEW;

HUMANS; IMMUNITY, HUMORAL; MOLECULAR DIAGNOSTIC TECHNIQUES; PROTEIN ARRAY ANALYSIS;

EID: 78650552101     PISSN: 14737159     EISSN: 17448352     Source Type: Journal    
DOI: 10.1586/erm.10.113     Document Type: Review

References (27)

1. Acierno JP, Braden BC, Klinke S, Goldbaum FA, Cauerhff A. Affinity maturation increases the stability and plasticity of the Fv domain of anti-protein antibodies. J. Mol. Biol. 374, 130-146 (2007).
2. McCafferty J, Griffiths AD, Winter G, Chiswell DJ. Phage antibodies: filamentous phage displaying antibody variable domains. Nature 348, 552-554 (1990).
3. Burton DR, Barbas CF 3rd, Persson MA, Koenig S, Chanock RM, Lerner RA. A large array of human monoclonal antibodies to type 1 human immunodeficiency virus from combinatorial libraries of asymptomatic individuals. Proc. Natl Acad. Sci. USA 88, 10134-10137 (1991).
4. Jespers LS, Roberts A, Mahler SM, Winter G, Hoogenboom HR. Guiding the selection of human antibodies from phage display repertoires to a single epitope of an antigen. Nat. Biotechnol. 12(9), 899-903 (1994).
5. Cortese R, Monaci P, Luzzago A et al. Selection of biologically active peptides by phage display of random peptide libraries. Curr. Opin. Biotechnol. 7, 616-621 (1996).
6. Fisch I, Kontermann RE, Finnern R et al. A strategy of exon shuffling for making large peptide repertoires displayed on filamentous bacteriophage. Proc. Natl Acad. Sci. USA 93(15), 7761-7766 (1996).
7. Folgori A, Tafi R, Meola A et al. A general strategy to identify mimotopes of pathological antigens using only random peptide libraries and human sera. EMBO J. 13(9), 2236-2243 (1994).
8. Irving RA, Coia G, Roberts A, Nuttall SD, Hudson PJ. Ribosome display and affinity maturation: from antibodies to single V-domains and steps towards cancer therapeutics. J. Immunol. Methods 248(1-2), 32-45 (2001).
9. Gold L. mRNA display: diversity matters during in vitro selection. Proc. Natl Acad. Sci. USA 98(9), 4825-4826 (2001).
10. Fukuda I, Kojoh K, Tabata N et al. In vitro evolution of single-chain antibodies using mRNA display. Nucleic Acids Res. 34(19), e127 (2006).
11. Douthwaite JA, Groves MA, Dufner P, Jermutus L. An improved method for an efficient and easily accessible eukaryotic ribosome display technology. Protein Eng. Des. Sel. 19(2), 85-90 (2006).
12. Haroun M, El-Sayed MM. Measurement of IgG levels can serve as a biomarker in newly diagnosed diabetic children. J. Clin. Biochem. Nutr. 41(1), 56-61 (2006).
13. Tan EM, Cohen AS, Fries JF et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 25, 1271-1277 (1982).
14. Desmetz C, Maudelonde T, Mang A, Solassol J. Identifying autoantibody signatures in cancer: a promising challenge. Expert Rev. Proteomics 6(4), 377-386 (2009).
15. Fritzler MJ. Challenges to the use of autoantibodies as predictors of disease onset, diagnosis and outcomes. Autoimmun. Rev. 7, 616-620 (2008).
16. Anderson L, Anderson NG. The human plasma proteome. Mol. Cell. Proteomics 1, 845-867 (2002).
17. Zhu H, Snyder M. Protein arrays and microarrays. Curr. Opin. Chem. Biol. 5(1), 40-45 (2001).
18. Anderson KS, LaBaer J. The sentinel within: exploiting the immune system for cancer biomarkers. J. Proteome Res. 4(4), 1123-1133 (2005).
19. Hudson ME, Pozdnyakova I, Haines K et al. Identification of differentially expressed proteins in ovarian cancer using highdensity protein microarrays. Proc. Natl Acad. Sci. USA 104(44), 17494-17499 (2007).
20. Kijanka G, Murphy D. Protein arrays as tools for serum autoantibody marker discovery in cancer. J. Proteomics 72, 936-944 (2009).
21. Li L, Chen A, Chaudhuri A et al. Compartmental localization and clinical relevance of MICA antibodies after renal transplantation. transplantation 89(3), 312-319 (2010).
22. Caiazzo RJ Jr, Tassinari OW, Ehrlich JR, Liu BC. Autoantibody microarrays for biomarker discovery. Expert Rev. Proteomics 4(2), 261-272 (2007).
23. Gnjatic S, Ritter E, Bchler MW et al. Seromic profiling of ovarian and pancreatic cancer. Proc. Natl Acad. Sci. USA 107(11), 5088-5093 (2010).
24. Andresen H, Grotzinger C. Deciphering the antibodyome - peptide arrays for serum antibody biomarker diagnostics. Curr. Proteomics 6, 1-12 (2009).
25. Andresen H, Grtzinger C, Zarse K, Kreuzer OJ, Ehrentreich-Frster E, Bier FF. Functional peptide microarrays for specific and sensitive antibody diagnostics. Proteomics 6(5), 1376-1384 (2006).
26. Schaller RR. Moores law: past, present and future. IEEE Spectrum 34(6), 52-59 (1997).
27. Collingridge D. Expression of concern - validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: a substudy of the EORTC 10994/BIG 00-01 clinical trial. Lancet Oncol. 11(9), 813-814 (2010). Pag 5-8 Plotkin SA. Immunologic correlates of protection induced by vaccination. Pediatr. Infect. Dis. J. 20(1), 63-75 (2001).